A PHASE II DOSE-RANGING, OPEN-LABELLED TRIAL OF FOSCARNET SALVAGE THERAPY FOR AIDS PATIENTS WITH SIGHT-THREATENING CMV RETINITIS WHO CANNOT BE TREATED WITH GANCICLOVIR DUE TO MYELOSUPPRESSION OR TREATMENT FAILURE: